免疫制御研究部門 研究業績


Chiba, Y., Mizoguchi, I., Furusawa, J., Hasegawa, H., Ohashi, M., Xu, M., Owaki, T., and Yoshimoto, T. Potent antitumor effects of Interleukin-27 by promoting differentiation of hematopoietic stem cells to antitumorigenic M1 macrophages. Cancer Res. accepted.


Mizoguchi, I., Ohashi, M., Chiba, Y., Hasegawa, H., Xu, M., Owaki, T., and Yoshimoto, T. Prediction of chemical respiratory and contact sensitizers by OX40L expression in dendritic cells using a novel 3D co-culture system. Frontiers Immunol. 04 August 2017, doi: 10.3389/fimmu.2017.00929.


Umemoto, T, Matsuzaki Y, Shiratsuchi Y, Yoshimoto T, Nakamura-Ishizu A, Petrich B, Yamato Y, Suda T. Integrin αvβ3 enhances the suppressive effect of interferon-γ on the maintenance of hematopoietic stem cells. EMBO J. 2017 Jul 3. pii: e201796771. doi: 10.15252/embj.201796771. 


Shimoura, N., Nagai, H., Fujiwara, S., Jimbo, H., Yoshimoto, T., Nishigori, C. Interleukin (IL)-18, cooperatively with IL-23, induces prominent inflammation and enhances psoriasis-like epidermal hyperplasia. Arch. Dermatol. Res. 2017 Mar 15. doi: 10.1007/s00403-017-1735-2.    


長谷川英哲、溝口 出、千葉祐規子、大橋美緒、徐明利、善本隆之:抑制性サイトカインIL-35による免疫制御、臨床免疫・アレルギー科、67, 37-43, 2017


神垣 隆、高原将司、照屋 剛、城間 寛、善本隆之、後藤重則:がん免疫療法—がん完治に向けての新たな治療法の探索—II.各論 がん免疫細胞療法、腫瘍ライセートを用いた固形腫瘍に対する樹状細胞ワクチン療法、日本臨床75巻2号、2017年2月1日    



Hasegawa, H., Mizoguchi, I., Chiba, Y., Ohashi, M., Xu, M. and Yoshimoto, T. Expanding diversity in molecular structures and functions of the IL-6/IL-12 heterodimeric cytokine family. Front. Immunol. 2016 Nov 4;7:479. DOI: 10.3389/fimmu.2016.00479


Kimura, Y., Nagai, N., Tsunekawa, N., Sato-Matsushita, M., Yoshimoto, T., Cua, D., Iwakura, Y., Yagita, H., Okada, F., Tahara, H., Saiki, I., Irimura, T. and Hayakawa, Y. IL-17A-producing CD30+ Vδ1 T cells drive inflammation-induced cancer progression. Cancer Sci. 2016, in press


Furusawa, J., Mizoguchi, I., Chiba, Y., Hisada, M., Kobayashi, F., Yoshida, H., Nakae, S., Tsuchida, A., Matsumoto, T., Ema, H., Mizuguchi, J., and Yoshimoto, T. Promotion of expansion and differentiation of hematopoietic stem cells by interleukin-27 into myeloid progenitors to control infection in emergency myelopoiesis. PLoS Pathog. 2016 May;12(3):e1005507.    


Miki, K., Nagaoka, K., Bohnenkamp, H., Yoshimoto, T., Maekawa, M., and Kamigaki, T. Dendritic cells pulsed with PepTivator® Ovalbumin induce both OVA-specific CD4+ and CD8+ T cells and cause antitumor effects in a mouse model of lymphoma. MACS&more 17(1), 7-10, 2016



Yoshimoto, T., Chiba, Y., Furusawa, J., Xu, M., Tsunoda, R., Higuchi, K., and Mizoguchi, I. Potential clinical application of interleukin-27 as an antitumor agent. Cancer Sci. 106 (9), 1103-1110, 2015.


Mizoguchi, I., Chiba, Y., Furusawa, J., Xu, M., Tsunoda, R., Higuchi, K., and Yoshimoto, T. Therapeutic potential of interleukin-27 against cancers in preclinical mouse models. Oncoimmunology, 2015 May 27;4(10):e1042200.


Toyota, H., Yanase, N., Yoshimoto, T., Harada, M., Kato, Y., and Mizuguchi, J. Vaccination with OVA-bound nanoparticles encapsulating IL-7 inhibits the growth of OVA-expressing E.G7 tumor cells in vivo. Oncol. Rep. 3, 292-296, 2015.


徐 明利、曲 寧、溝口 出、古澤純一、千葉祐規乃、伊藤正裕、善本隆之:炎症疾患におけるTh17関連サイトカインIL-17, IL-22, IL-23の役割、炎症と免疫23(2), 170-176, 2015


樋口要、徐明利、善本隆之:特集 知っておきたい脾臓の話題 脾臓の機能検査、小児外科 47(3), 250-3, 2015



Mizoguchi, I., Yoshimoto, T., Katagiri, S., Furusawa, J., Chiba, Y., Mizuguchi, J., Tauchi, T., Ohyashiki, J. H., and Ohyashiki, K. Immunologic control of chronic myeloid leukemia leading to treatment-free remission. J. Hematol. Transfus. 2(3): 1024, 2014.


Ohyashiki, J. H., Ohtsuki, K., Mizoguchi, I., Yoshimoto, T., Katagiri, S., Umezu, T., and Ohyashiki, K. Down-regulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: A possible molecular classifier to stop imatinib safely. Drug Des. Devel. Ther.8, 1151-1159, 2014.


Yoshimoto, T., Mizoguchi, I., Katagiri, S., Tauchi, T., Furusawa, J., Chiba, Y., Mizuguchi, J., Ohyashiki, J. H., and Ohyashiki, K. Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse. Oncoimmunology 2014 May 14;3:e28861.


Terayama, H., Yoshimoto, T., Hirai, S., Naito, M., Qu, N., Hatayama, N., Hayashi, S., Mitobe, K., Furusawa, J., Mizoguchi, I., Kezuka, T., Goto, H., Suyama, K., Moriyama, H., Sakabe, K., and Itoh, M. Contribution of IL-12/IL-35 common subunit p35 to maintaining the testicular immune privilege. PLoS One2014 Apr 23;9(4):e96120.


Fujiwara, S., Nagai, H., Shimoura, N., Oniki, S., Yoshimoto, T., and Nishigori, C. Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist. J. Invest. Dermatol. 134, 1884-1892, 2014.


寺山隼人、善本隆之、内藤宗和、平井宗一、曲寧、畑山直之、林省吾、金沢輝久、隅山香織、坂部貢、伊藤正裕:精巣内インターロイキン-35の役割Reprod. Immunol. Biol. 29 (1), 13-23, 2014


寺山隼人、伊藤正裕、内藤宗和、平井宗一、曲寧、畑山直之、林省吾、田村摩衣子、金沢輝久、善本隆之、坂部貢:サイトカインによる精巣免疫特権の維持〜IL-35の役割とその病態生理学的意義について〜、日本病態生理学会雑誌23 (3), 46-49, 2014



Chiba, Y., Mizoguchi, I., Mitobe, K., Higuchi, K.,Nagai, H., Nishigori, C., Mizuguchi, J., and Yoshimoto, T. IL-27 enhances the expression of TRAIL and TLR3 in human melanomas and inhibits their tumor growth in cooperation with a TLR3 agonist poly(I:C) partly in a TRAIL-dependent manner. PLoS One2013 Oct 14;8(10):e76159. 


Qu, N, Xu, M., Mizoguchi, I., Furusawa, J., Kaneko, K., Watanebe, K., Mizuguchi, J., Itoh, M., Kawakami, Y., and Yoshimoto, T. Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22 and IL-23, in inflammatory diseases. Clin. Dev. Immunol.,  2013;2013:968549. doi: 10.1155/2013:968549.


Mizoguchi, I., Yoshimoto, T., Katagiri, S., Mizuguchi, J., Tauchi, T., Kimura, Y., Inokuchi, K., Ohyashiki, J. H., and Ohyashiki, K. Sustained up-regulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Sci. 104, 1146-1153, 2013.


Nakajima, K., Maekawa, Y., Kataoka, K., Ishifune, C., Nishida, J., Arimochi, H., Kitamura, A., Yoshimoto, T., Tomita, S., Nagahiro, S., and Yasutomo, K. The ARNT-Stat3 axis regulates the differentiation of intestinal intraepithelial TCRαβ+CD8ααcells. Nat. Commun. 2013;4:2112. doi: 10.1038/ncomms3112.


Mizoguchi, I., Higuchi, K., Mitobe, K., Tsunoda, R., Mizuguchi, J., and Yoshimoto, T. Interleukin-27: Regulation of immune responses and disease development by a pleiotropic cytokine with pro- and anti-inflammatory properties. In Cytokine Frontiers: Regulation of Immune Responses in Health and Disease. Editors: Yoshimoto, T. and Yoshimoto, T. Springer, in press


Shimizu, M., Ogura, K., Mizoguchi, I., Chiba, Y., Higuchi, K., Ohtsuka, H., Mizuguchi, J., and Yoshimoto, T. IL-27 promotes nitric oxide production induced by LPS through STAT1, NF-kB and MAPKs. Immunobiology 218, 628-634, 2013.



Suzukawa,  M., Morita, H., Nambu, A., K. Arae, T. Ohno, Shimura, E., Shibui, A., Yamaguchi, S., Suzukawa, K., Nakanishi, W., Oboki, K., Kajiwara, N., Ohno, T., Ishii, A., Korner, H., Cua, J.C., Suto, H., Yoshimoto, T., Iwakura, Y., Yamasoba, T., Ohta, K., Sudo, K., Sito, H., Okumura, K., Broide, D., Matsumoto, K., and Nake, S. Epitherlial cell-derived IL-25, but not Th17 cell-derived IL-17 or IL-17F, is crucial for murine asthma. J. Immunol. 189, 3641-3652, 2012.

Xu, M., Masakatsu, T., Oikawa, K., Nishi, H., Isaka, K., Yoshimoto, T., Ohyashiki, J. and Kuroda, M. Identification of a novel role of Septin 10 in spindle-checkpoint and Paclitaxel-resistance in human cancers through a functional genomics screen. Cancer Sci. 103, 821-827, 2012.

Fujiwara, S., Nagai, H., Oniki, S., Yoshimoto, T., and Nishigori, C. Interleukin (IL)-17 versus IL-27: opposite effects on TNF-α-induced chemokine production in human keratinocytes. Exp. Dermatol. 21, 70-72, 2012. 

千葉祐規乃、溝口出、森嶋紀子、徐明利、善本隆之:サイトカインのすべて IL-27、臨床免疫・アレルギー科、57 (Suppl. 21), 172-183, 2012

溝口出、森嶋紀子、善本隆之:サイトカインのすべて IL-30、臨床免疫・アレルギー科、57 (Suppl. 21), 188-196, 2012

徐明利、千葉祐規乃、善本隆之:サイトカインのすべて IL-35、臨床免疫・アレルギー科、57 (Suppl. 21), 220-230, 2012

太田裕士、徐明利、溝口出、高梨正勝、須藤カツ子、黒田雅彦、善本隆之、粕谷和彦、土田明彦、畝崎榮:DCワクチンをリンパ節投与した際の局所滞留性と免疫誘導能の検討、東京医科大学雑誌 70 (4), 444-449, 2012

溝口出、樋口要、大塚裕美、善本隆之:抑制性サイトカインIL-10とIL-35による免疫反応の恒常性の維持、細胞工学、31 (No. 7), 765-771, 2012


Xu, M., Morishima, N., Mizoguchi, I., Chiba, Y., Fujita, K., Kuroda, M., Iwakura, Y., Cua, D. J., Yasutomo, K., Mizuguchi, J. and Yoshimoto, T. Regulation of the development of acutehepatitis by IL-23 through IL-22 and IL-17 production. Eur. J. Immunol. 41, 2828-2839, 2011.

Kuramoto, T., Fujii, R., Nagai, H., Belladonna, M.L., Yoshimoto, T., Kohjimoto, Y., Inagaki, T. and Hara, I. IL-23 gene therapy for mouse bladder tumor cell lines. BJU Int. 108, 914-921, 2011.

Pickens, S.R., Volin, M.V., Mandelin II, A.M., Matsui, M., Yoshimoto, T. and Shahrara, S. Local expression of IL-27 ameliorates collagen induced arthritis. Arthritis Rheum. 63, 2289-2298, 2011.

Kamiya, S., Okumura, M., Chiba, Y., Nakamura, C., Fukawa, T., Nimura, N., Mizuguchi, J., Wada, S. and Yoshimoto, T. IL-27 suppresses RANKL expression in CD4+ T cells in part through STAT3. Immunol. Let. 138, 47-53, 2011.

奥村昌恵、徐明利、善本隆之:IL-12、Seriesモデル動物利用マニュアル、免疫疾患—疾患モデルの作製と利用—、(株)エルアイシー、266-275, 2011

千葉祐規乃、溝口出、善本隆之:Th1/Th2、Seriesモデル動物利用マニュアル、免疫疾患—疾患モデルの作製と利用—、(株)エルアイシー、147-157, 2011.

善本隆之(監修):赤ちゃんのすごい免疫パワー、AERA with Baby12月号、21, 32-46, 2011.

M. S. Alam, Y. Maekawa, A. Kitamura, K. Tanigaki, T. Yoshimoto, K. Kishiara, and K. Yasutomo. Notch signaling drives IL-22 secretion in CD4+ T cells by stimulating the aryl hydrocarbon receptor. Proc. Natl. Acad. Sci. USA 107, 5943-5948, 2010.

N. Morishima, I. Mizoguchi, M. Okumura, Y. Chiba, M. Xu, M. Shimizu, M. Matsui, J. Mizuguchi, and T. Yoshimoto. A pivotal role for interleukin-27 in CD8+ T cell functions and generation of cytotoxic T lymphocytes (Review). J. Biomed. Biotech. 2010:605483.

Xu, M., Mizoguchi, I., Morishima, N., Chiba, Y., Mizuguchi, J. and Yoshimoto, T. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23 and IL-27 (Review). Clin. Dev. Immunol. 2010. pii: 832454.

H. Nagai, S. Oniki, S. Fujiwara, T. Yoshimoto, and C. Nishigori. Anti-melanoma immunotherapy: Clinical and preclinical applications of IL-12 family members (Review). Immunotherapy 5: 697-709, 2010.

H. Nagai, S. Oniki, S. Fujiwara, M. Xu, I, Mizoguchi, T. Yoshimoto, and C. Nishigori. Antitumor activities of interleukin-27 on melanoma (Review). Endocr. Metab. Immune Disord. Drug Targets 10, 41-46, 2010.

溝口出、千葉祐規乃、善本隆之:インターロイキン19 (IL-19)から最新のサイトカインIL-35まで、日本臨床、68, 86-92, 2010

森嶋紀子、徐明利、奥村昌恵、善本隆之:Tr1細胞の分化を誘導するサイトカイン、臨床免疫・アレルギー科、53, 358-364, 2010

溝口出、森嶋紀子、奥村昌恵、千葉祐規乃、善本隆之:抗炎症性サイトカインIL-10とIL-35、臨床検査、54, 607-613, 2010

森嶋紀子、千葉祐規乃、善本隆之:抗炎症性サイトカインIL-10とIL-35、実験医学、28, 1916-1922, 2010

徐明利、溝口出、善本隆之:癌とサイトカイン、実験医学、28, 1997-2003, 2010

善本隆之:ケモカインの生物活性・臨床的意義と検査法/接着分子の種類・性質と検査法 in 臨床検査法提要、改訂第33版、金井正光編集、金原出版、793-802, 2010

S. Tanaka, T. Yoshimoto, T. Naka, K. Nishida, M. Murakami, T. Hirano, S. Nakae, Y. Iwakura, D. Cua and M. Kubo. Natural occurring IL-17 producing T cells regulate the initial phase of neutrophil mediated airway responses. J. Immunol. 183, 7523-7530, 2009.

T. Yoshimoto, N. Morishima, M. Okumura, Y. Chiba, M. Xu, and J. Mizuguchi. Interleukins and cancer immunotherapy (Review). Immunotherapy 1, 825-844, 2009.

N. Morishima, I. Mizoguchi, K. Takeda, J. Mizuguchi, and T. Yoshimoto. TGF-β is necessary for induction of IL-23R and Th17 differentiation by IL-6 and IL-23. Biochem. Biophys. Res. Commun. 286, 105-110, 2009.

P. Hu, H.D. Hu, M. Chen, M.L. Peng, L. Tang, K.F. Tang, M. Matsui, M.L. Belladonna, T. Yoshimoto, D.Z. Zhang, R. Xiang, and H. Ren. Expression of Interlukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Mol. Immunol. 46, 1654-1662, 2009.

M. Matsui, T. Kishida, H. Nakano, K. Yoshimoto, M. Shin-Ya, T. Shimada, S. Nakai, J. Imanishi, T. Yoshimoto, Y. Hisa, and O. Mazda. IL-27 activates natural killer (NK) cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity. Cancer Res. 69, 2523-2530, 2009.

千葉祐規乃、奥村昌恵、善本隆之:最新の抗炎症性サイトカインIL-35、細胞工学、28, 1153-1154, 2009

森嶋紀子、徐明利、善本隆之:抗炎症性サイトカインIL-10と制御性T細胞、細胞工学、28, 1137-1141, 2009

武田泰隆、榮光子、善本隆之、森本純司、清水本武、柳衛宏宣、螺良愛郎:正電荷ポリマーを用いたFasリガンド(FasL)遺伝子導入による乳癌遺伝子治療へ向けた基礎的研究、乳癌基礎研究、18, 17-22, 2009

善本隆之:学会レポート、キーストーンシンポジウムに参加して、JSI Newsletter 18, 25, 2009

T. Yoshimoto, N. Morishima, I. Mizoguchi, S. Oniki, H. Nagai, M. Oka, C. Nishigori, and J. Mizuguchi. Anti-proliferative activity of IL-27 on melanoma. J. Immunol. 180, 6527-6535, 2008. 

H. Kosaka, T. Yoshimoto, T. Yoshimoto, J. Fujimoto, and K. Nakanishi. IFN-γ is a therapeutic target molecule for prevention of postoperative adhesion formation. Nat. Med. 14, 437-441, 2008. 

T. Owaki, M. Asakawa, N. Morishima, I. Mizoguchi, K. Takeda, F. Fukai, J. Mizuguchi, and T. Yoshimoto. STAT3 is indispensable to IL-27-mediated cell proliferation but not to IL-27-induced Th1 differentiation and suppression of proinflammatory cytokine production. J. Immunol. 180, 2903-2911, 2008. 

J. Seita, M. Asakawa, J. Ooehara, S. Takayanagi, Y. Morita, N. Watanabe, K. Fujita, M. Kudo, J. Mizuguchi, H. Ema, H. Nakauchi, and T. Yoshimoto. Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood, 111, 1903-1912, 2008. 

T. Yoshimoto, N. Morishima, M. Okumura, Y. Chiba, K. Onishi, I. Mizoguchi, and J. Mizuguchi.Interleukin-27: biological properties and application to immunotherapy of cancer (Review). Trend. Cancer Res. 4, 93-103, 2008.

善本隆之:IL-27の抗腫瘍効果、炎症と免疫、16, 24-30, 2008

T. Yoshimoto, T. Yoshimoto, K. Yasuda, J. Mizuguchi, and K. Nakanishi. IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells; a novel therapeutic way for Th2-mediated allergic inflammation. J. Immunol. 179, 4415-4423, 2007. 

S. Kohyama, S. Ohno, A. Isoda, O. Moriya, H.Hayashi, Y. Iwakura, T. Yoshimoto, T. Akatsuka, and M. Matsui. IL-23 enhances host defense against vaccinia virus infection via a mechanism partly involving IL-17. J. Immunol. 179, 3917-3925, 2007. 

A. P. Nigg, S. Zahn, D. Ruckerl, C. Hölscher, T. Yoshimoto, J. M. Ehrchen, F. Wölbing, M. C. Udey, and E. von Stebut. Dendritic cell-derived IL-12p40 homodimer contributes to susceptibility in cutaneous leishmaniasisi in BALB/c mice. J. Immunol. 178, 7251-7258, 2007. 

S. Kamiya, C. Nakamura, T. Fukawa, K. Ono, T. Ohwaki, T. Yoshimoto, and S. Wada. Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation. J. Bone Miner. Metab. 25, 277-285, 2007.

善本隆之:IL-23をめぐって、Annual Review 2007呼吸器、中外医学社、41-48, 2007

大脇敏之、森嶋紀子、深井文雄、水口純一郎、善本隆之:IL-6/IL-12ファミリーサイトカインIL-27による免疫反応の制御 ヘルパーT細胞の分化制御の観点から、臨床免疫、47, 290-297, 2007

清水本武、島村真里子、善本隆之:IL-27の血管新生抑制作用、臨床免疫、47, 298-302, 2007

善本隆之:IL-23IL-27 -Th17の光と陰-、免疫ニュースレター、15, 15-16, 2007

武田泰隆、榮光子、善本隆之、森本純司、清水本武、柳衛宏宣:正電荷ポリマーによる乳癌細胞に対する遺伝子導入の基礎的研究、乳癌基礎研究、16, 43-49, 2007

溝口出、森嶋紀子、水口純一郎、善本隆之:IL-6/IL-12関連サイトカインIL-27による免疫制御、臨床免疫、48, 576-584, 2007

T. Owaki, M. Asakawa, F. Fukai, J. Mizuguchi, and T. Yoshimoto. IL-27 induces Th1 differentiation via p38 MAPK/T-bet- and ICAM-1/LFA-1/ERK-dependent pathways. J. Immunol.177, 7579-7587, 2006. 

D. Ruckerl, M. Hessmann, T. Yoshimoto, S. Ehlers, and C. Hölscher. Alternatively activated macrophages express the IL-27 receptor alpha chain WSX-1. Immunobiology 211, 427-436, 2006.

S. Oniki, H. Nagai, T. Horikawa, J. Furukawa, M. L. Belladonna, T. Yoshimoto, I. Hara, and C. Nishigori. Interleukin-23 and interleukin-27 exert quite distinct antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res. 66, 6395-6404, 2006.

S. Ohno, O. Moriya, T. Yoshimoto, H. Hayashi, T. Akatsuka, and M. Matsui. Immunogenic variation between multiple HLA-A*0201-restricted, hepatitis C virus-derived epitopes for cytotoxic T lymphocytes. Viral Immunol. 19, 458-467, 2006.

M. Shimizu, M. Shimamura, T. Owaki, M. Asakawa, K. Fujita, M. Kudo, Y. Iwakura, Y. Takeda, J. Mizuguchi, and T. Yoshimoto. Antiangiogenic and antitumor activities of interleukin-27 (IL-27).J. Immunol. 176, 7317-7324, 2006.

T. Owaki, M. Asakawa, S. Kamiya, K. Takeda, F. Fukai, J. Mizuguchi, and T. Yoshimoto. IL-27 suppresses CD28-medicated IL-2 production through SOCS3. J. Immunol. 176, 2773-2780, 2006.

M. Shimizu, T. Yoshimoto, M. Sato, A. Matsuzawa, and Y. Takeda. Frequency and resistance of CD95 (Fas/Apo-1) gene-transfected tumor cells to CD95-mediated apoptosis by the elimination and methylation of integrated DNA. Int. J. Cancer 119, 585-592, 2006.

善本隆之、水口純一郎:新しいIL-6/IL-12ファミリーサイトカインIL-27による免疫制御、東京医科大学雑誌、64, 1-11, 2006

森嶋紀子、水口純一郎、善本隆之:IL-6/IL-12関連サイトカインIL-27による細胞傷害性Tリンパ球誘導の増強、臨床免疫、44, 579-584, 2006

大脇敏之、浅川正幸、深井文雄、水口純一郎、善本隆之:Th1細胞分化におけるIL-27の役割、臨床免疫、44, 579-584, 2006

H. S. Koh, A. Matsui, S. Mimura, M. Inao, E. Saitoh, A. Ohno, S. Nagoshi, T. Yoshimoto, S. Mochida, and K. Fujiwara. Increased cytoprotective function in the liver of transgenic mice expressing osteopontin in hepatocytes. Hepatol. Res. 32, 46-51, 2005.

E. Saitoh, A. Matsui, M. Inao, S. Mimura, H. Koh, A. Ohno, S. Nagoshi, H. Kayano, T. Yoshimoto, S. Mochida, and K. Fujiwara. Extrahepatic manifestations in transgenic mice of osteopontin in hepatocytes-A clue to advent of pathological state in various organs of chronic hepatitis C patients. Hepatol. Res. 31, 197-202, 2005. 

M. Matsui, O. Moriya, T. Yoshimoto, and T. Akatsuka. T-bet is required for protective immunity to vaccinia virus infection. J. Virol. 79, 12798-12806, 2005.

T. Owaki, N. Morishima, M. Asakawa, Y. Iwakura, F. Fukai, M. Matsui, J. Mizuguchi, and T. Yoshimoto. A role for IL-27 in early regulation of Th1 differentiation. J. Immunol. 175, 2191-2200, 2005. 

N. Morishima, T. Owaki, M. Asakawa, S. Kamiya, J. Mizuguchi, and T. Yoshimoto. Augmentation of effector CD8+ T cell generation with enhanced granzyme B expression by IL-27.J. Immunol. 175, 1686-1693, 2005. C. 

Hölscher, A. Hölscher, T. Yoshimoto, H. Yoshida, T. Mak, C. Saris, and S. Ehlers. The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J. Immunol. 174, 3534-3544, 2005.

M. Shimizu, T. Yoshimoto, M. Sato, J. Morimoto, A. Matsuzawa, and Y. Takeda. Roles of CXC chemokines and macrophages in the recruitment of inflammatory cells and tumor rejection induced by Fas/Apo-1 (CD95) ligand-expressing tumor. Int. J. Cancer 114, 926-935, 2005. 

T. Yoshimoto, T. Owaki, M. Asakawa, N. Morishima, S. Kamiya, and J. Mizuguchi. A novel IL-6/IL-12 family cytokine IL-27 and its antitumor activity. Gene Ther. Mol. Biol. 9, 7-14, 2005. 

J. Scheller, B. Schuster, C. Hölscher, T. Yoshimoto, and S. Rose-John. No inhibition of IL-27 signaling by sgp130Fc. Biochem. Biophys. Res. Commun. 326, 724-728, 2005. 

善本隆之、久田将之、清水本武、島村真里子、水口純一郎:新しいIL-6/IL-12ファミリーサイトカインIL-27の抗腫瘍効果、臨床免疫、43, 123-128, 2005

善本隆之:ケモカインの種類・性質と検査法/接着分子の種類・性質と検査法 in 臨床検査法提要、改訂第32版、金井正光編集、金原出版、826-835, 2005

善本隆之:第10章 サイトカインとそのシグナル伝達系、免疫学ハンドブック、オーム社、303-314, 2005

善本隆之:最近の新しいサイトカインIL-25, IL-26, IL-27、今日の移植、18, 515-519, 2005

大脇敏之、森嶋紀子、深井文雄、水口純一郎、善本隆之:IL-6/IL-12ファミリーサイトカインIL-27によるTh1反応の増強、臨床免疫、44, 579-584, 2005

S. Kamiya, T. Owaki, N. Morishima, M. Asakawa, F. Fukai, J. Mizuguchi, and T. Yoshimoto. An indispensable role for STAT1 in IL-27-induced T-bet expression but not proliferation of naive CD4+ T cells. J. Immunol. 173, 3871-3877, 2004.

K. Hata, T. Yoshimoto, and J. Mizuguchi. CD40 ligand rescues inhibitor of differentiation 3-medaited G1 arrest induced by anti-IgM in WEHI-231 B lymphoma cells. J. Immunol. 173, 2453-2461,2004.

T. Yoshimoto, K. Okada, N. Morishima, S. Kamiya, T. Owaki, M. Asakawa, F. Fukai, Y. Iwakura, and J. Mizuguchi. Induction of IgG2a class switching in B cells by IL-27. J. Immunol.173, 2479-2485,2004.

S. Mimura, S. Mochida, M. Inao, A. Matsui, S. Nagoshi, T. Yoshimoto, and K. Fujiwara. Massive liver necrosis after provocation of imbalance between Th1 and Th2 immune reactions in osteopontin transgenic mice. J. Gastroenterol. 39, 867-872, 2004.

Mochida, T. Yoshimoto, S. Mimura, M. Inao, A. Matsui, A, Ohno, H. Koh, E. Saitoh, S. Nagoshi, and K. Fujiwara. Transgenic mice expressing osteopontin in hepatocytes as a model of autoimmune hepatitis. Biochem. Biophys. Res. Commun. 317, 114-120, 2004.

M. Matsui, O. Moriya, M. L. Belladoma, S. Kamiya F. A. Lemonnier, T. Yoshimoto, and T. Akatsuka. Adjuvant activities of novel cytokines, interleukine (IL)-23 and IL-27 for induction of hepatitis C virus-specific cytotoxic T lymphocytes in HLA-A*0201 transgenic miceJ. Virol. 73, 9093-9104, 2004.

M. Hisada, S. Kamiya, K. Fujita, M. L. Belladonna, T. Aoki, Y. Koyanagi, J. Mizuguchi, and T. Yoshimoto. Potent anti-tumor activity of interleukin-27. Cancer Res. 64, 1152-1156, 2004.

M. Hisada, T. Yoshimoto, S. Kamiya, Y. Magami, H. Miyaji, T. Yoneto, K. Tamada, T. Aoki, Y. Koyanagi, and J. Mizuguchi. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT. Cancer Gene Therapy 11, 280-288, 2004.

善本隆之:IL-12シグナル伝達 –Sphingosine Kinase 2による制御-、臨床免疫、41, 460-465, 2004

武田泰隆、茶山和敏、柳衛宏宣、善本隆之、森本純司、清水元武:Fasリガンド(FasL)遺伝子導入癌細胞による抗腫瘍免疫誘導の乳ガン遺伝子治療応用への基礎的研究、乳癌基礎研究、13, 57-65, 2004

M. Shimizu, T. Yoshimoto, A. Matsuzawa, and Y. Takeda. Modification of tumor cells with Fas (CD95) antigen gene and Fas ligand (CD95L) gene transfection by electroporation for immunotherapy of cancer. Mol. Biotechnol. 25, 79-87, 2003.

X. Z. Jiang, H. Toyota, T. Yoshimoto, E. Takada, H. Asakura, and J. Mizuguchi. Anti-IgM-induced down-regulation of nuclear Thy28 protein expression in Ramos B lymphoma cells.Apoptosis 8, 509-519, 2003.

X. Z. Jiang, H. Toyota, E. Takada, T. Yoshimoto, T. Kitamura, J. Yamada, and J. Mizuguchi. Modulation of mThy28 nuclear protein expression during thymocyte development. Tissue Cell 35, 471-478, 2003.

H. Suzuki. T. Hotta, T. Koyama, M. Komagata, A. Imakiire, N. Yanase, T. Yoshimoto, and J. Mizuguchi. Retrovirus-mediated transduction of TRAIL and chemotherapeutic agents co-operatively induce apoptotic cell death in both sarcoma and myeloma cells. Anticancer Res. 23, 3247-3254, 2003

T. Yoshimoto, M. Furuhata, S. Kamiya, M. Hisada, H. Miyaji, Y. Magami, K. Yamamoto, H. Fujiwara, and J. Mizuguch. Positive modulation of IL-12 signaling by sphingosine kinase 2 associating with IL-12Rb1 cytoplasmic region. J. Immunol. 171, 1352-1359, 2003.

Y. Aramaki, I. Lee, H. Arima, T. Sakamoto, Y. Magami, T. Yoshimoto, J. Mizuguchi, Y. Koyanagi, T. Nikaido, and S. Tsuchiya. Efficient gene transfer to hepatoblastoma cells through asialoglycoprotein recepotr and expression under the control of the cyclin A promoter. Biol. Pharm. Bull. 26, 357-360, 2003

D. Nakayama, Y. Magami, T. Azuma, H. Inokuchi, M. Furukawa, J. Ohyashiki, T. Yoshimoto, J. Mizuguchi, F. Moriyasu, K. Kawai, and T. Hattori. Turnover of acinar and islet cells in the pancreas of monosodium glutamate-treated obese mice. Obes Res. 11, 87-94, 2003.

H. Toyota, N. Yanase, T. Yoshimoto, M. Moriyama, T. Sudo, and J. Mizuguchi. Calpain-induced Bax-cleavage product is a more potent inducer of apoptotic cell death than wild-type Bax. Cancer Lett. 189, 221-230, 2003.

H. Miyaji, T. Yoshimoto, H. Asakura, A. Komachi, S. Kamiya, M. Takasaki, and J. Mizuguchi.Molecular cloning and characterization of the mouse thymocyte protein gene. Gene 297, 189-196, 2002.


T. Yoneto, S. Waki, T. Takai, Y. Tagawa, Y. Iwakura, J. Mizuguchi, H. Nariuchi, and T. Yoshimoto. A critical role of Fc receptor-mediated antibody-dependent phagocytosis in the host resistance to blood-stage Plasmodium berghei XAT infection. J. Immunol. 166, 6236-6241, 2001.

T. Yasuda, T. Yoshimoto, A. Tsubura and A. Matsuzawa. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-Faslprcg/Faslprcg mice. Cell. Immunol. 210, 77-86, 2001

Y. Niita, S. Kawamoto, F. Tashiro, H. Aihara, T. Yoshimoto, H. Nariuchi, K. Tabayashi, and J. Miyazaki. 
IL-12 plays a pathologic role at the inflammatory loci in the development of diabetes in NOD mice. J. Autoimmun. 16, 97-104, 2001.

A. Matsuzawa, T. Yasuda, S. Sakamoto, H. Nagase, H. Nakano, and T. Yoshimoto . Characterization of mouse mammary tumor virus-induced migration of lymphoid cells into lympho nodes. Scand. J. Immunol. 53, 553-562, 2001.

M. Shimizu, A. Fontana, Y. Takeda, T. Yoshimoto, A. Tsubura, and M. Matsuzawa. Fas/Apo-1 (CD95)-mediated apoptosis of neutrophilis with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity. Cell. Immunol. 207, 41-48, 2001.


Y. Zhang, T. Yasuda, C. -R. Wang, T. Yoshimoto, H. Nagase, M. Takamoto, A. Tsubura, M. Kimura, and A. Matsuzawa. A pivotal role of cell-bound but not soluble CD4 molecules in full development of lupus-like manifestations in MRL-Faslprcg/ Faslprcg mice. Clin. Exp. Immunol.122, 124-132, 2000.

A. Matsuzawa, T. Yasuda, Y. Zhang, H. Nagase, T. Yoshimoto, M. Kimura, and A. Tsubura Alleviation of renal disease andlymphadenopathy in MRL-Faslprcg/ Faslprcg (MRL-lprcg) mice neonatallyinfected with mouse mammary tumor virus (MMTV) encoding superantigen strongly reactive with TCR Vb8.2 element. Viral Immunol. 13, 297-311, 2000.

C. -R. Wang, A. Hino, T. Yoshimoto, H. Nagase, T. Kato, K. Hirokawa, A. Matsuzawa, and H. Nariuchi. Impaired delayed-type hypersensitivity response in mutant mice secreting soluble CD4 without expression of membrane-bound CD4. Immunol. 100, 309-316, 2000.

T. Yoshimoto, C. -R. Wang, T. Yoneto, A. Matsuzawa, W. W. Cruikshank, and H. Nariuchi A role of IL-16 in delayed-type hypersensitivity (DTH) reaction. Blood 95, 2869-2874, 2000.


M. Shimizu, A. Fontana, Y. Takeda, H. Yagita, T. Yoshimoto, and A. Matsuzawa. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma Neuro-2a cells. J. Immunol. 162, 7350-7357, 1999.

T. Yoneto, T. Yoshimoto, C. -R. Wang, Y. Takahama, M. Tsuji, S. Waki, and H. Nariuchi. Gamma interferon is critical for protective immunity to infection with blood-stage Plasmodium berghei XAT but neither NO production nor NK cell activation is critical. Infect. Immun. 67, 2349-2356, 1999.


T. Yoshimoto, T. Yoneto, C. -R. Wang, T. Yasuda, A. Matsuzawa, Y. Nitta, J. Miyazaki, S. Waki, and H. Nariuchi. Interleukin-12 p40 transgenic mice. In Proceedings of the 10th International Congress of Immunology.   Eds. G. P. Talwar, I. Nath, N. K. Ganguly and K. V. S. Rao, Moduzzi Editore, Italy, pp 1651-1654, 1998.

T. Yoshimoto, H. Nagase, T. Yoneto, J. Inoue, and H. Nariuchi. Interleukin-12 expression in B cells by transformation with Epstein-Barr virus. Biochem. Biophys. Res. Commun. 252, 556-560, 1998.

M. Shimizu, Y. Takeda, H. Yagita, T. Yoshimoto, and A. Matsuzawa. Antitumor activity exhibited by Fas ligand (CD95L) overexpressed on lymnphoid cells against Fas+ tumor cells. Cancer Immunol. Immunother. 47, 143-148, 1998.

T. Yoshimoto,  Y. Takahama, C. -R. Wang, T. Yoneto, S. Waki, and H. Nariuchi. A pathogenic role of IL-12 in Plasmodium berghei NK65 infection. J. Immunol. 160, 5500-5505, 1998.

H. Nagase, T. Yoshimoto, C. -R. Wang, T. Shiroishi, A. Matsuzawa, and H. Nariuchi. Novel mutant mice secreting soluble CD4 without expression of membrane-bound CD4. Eur. J. Immunol. 28, 403-412, 1998.

T. Yoshimoto, C. -R. Wang, T. Yoneto, S. Waki, S. Sunaga, Y. Komagata, M. Mitsuyama, J. Miyazaki, and H. Nariuchi. Reduced Th1 responses in interleukin-12 p40 transgenic mice. J. Immunol. 160, 588-594, 1998.

T. Yoshimoto, T. Yoneto, S. Waki, and H. Nariuchi. IL-12 dependent mechanisms in the clearance of blood-stage murine malaria Plasmodium berghei XAT, an attenuated variant of Plasmodium berghei NK65. J. Infec. Dis. 177, 1674-1681, 1998.

T. Yoshimoto, H. Nagase, T. Ishida, J. Inoue, and H. Nariuchi. Induction of interleukin-12 p40 transcript by CD40 ligation via activation of nuclear factor-kB. Eur. J. Immunol. 27, 3461-3470, 1997.

H. Nakano, T. Tamura, T. Yoshimoto, H. Yagita, M. Miyasaka, E. C. Butcher, H. Nariuchi, T. Kakiuchi, and A. Matsuzawa. Genetic defect in T lymphocyte-specific homing into peripheral lymph nodes. Eur. J. Immunol. 27, 215-221, 1997.

M. Shimizu, T. Yoshimoto, S. Nagata, and A. Matsuzawa. A trial to kill tumor cells through Fas (CD95)-mediated apoptosis in vivo. Biochem. Biophys. Res. Commun. 228, 375-379, 1996.

T. Yoshimoto, H. Nagase, H. Nakano, A. Matsuzawa, and H. Nariuchi. Deletion of CD4+ T cells by mouse mammary tumor virus (FM) superantigen with broad specificity of T cell receptor 
b-chain variable region. Virology 223, 387-391, 1996.

H. Nakano, T. Yoshimoto, H. Nariuchi, T. Kakiuchi, and A. Matsuzawa. Deletion of perioheral Vb14+ T cells by Mtv-2-encoded viral superantigen preceded by blastogenesis and DNA synthesis but not by specific expansion. Cellular Immunol. 168, 281-290, 1996.

T. Yoshimoto, K. Kojima, T. Funakoshi, Y. Endo, T. Fujita, and H. Nariuchi. Molecular cloning and characterization of murine interleukin-12 genes. J. Immunol. 156, 1082-1088, 1996.

A. Matsuzawa, H. Nakano, S. Sakamoto, T. Yoshimoto, and H. Nariuchi. Dramatic hyperplasia of Mtv-2+ lymph node grafts in Mtv-2- recipients and selevtive stimulation of Vb14+ T cells in recipients' lymph nodes in the DDD mouse. J. Immunol. 154, 1644-1652, 1995.

A. Matsuzawa, H. Nakano, T. Yoshimoto, and K. Sayama. Biology of mouse mammary tumor virus (MMTV). Cancer Lett. 90, 3-11, 1995.

T. Yoshimoto, H. Nagase, H. Nakano, A. Matsuzawa, and H. Nariuchi. A Vb8.2-specific superantigen form exogenous mouse mammary tumor virus carried by FM mice. Eur. J. Immunol.24, 1612-1619, 1994.

H. Nakano, T. Yoshimoto, T. Kakiuchi, and A. Matsuzawa. Nonspecific augmentation of lymph node Tcells and I-E-independent selective deletion of Vb14+ T cell by Mtv-2 in the DDD mouse.Eur. J. Immunol. 23, 2434-2439, 1993.

V. K. Tsiagbe, J. Asakawa, T. Yoshimoto, S. Y. Cho, D. Meruelo, and G. J. Thorbecke. MTV encoded superantigen expression in B lymphoma cells in SJL mice as a stimulus for "reversed immunological surveillance". In Superantigens; editors: E. Palmer and B. Huber, publishehers: Cold Spring Harbor Press, Cold Spring Harbor, New York, pp. 93-115, 1993. 

V. K. Tsiagbe, T. Yoshimoto, J. Asakawa, S. Y. Cho, D. Meruelo, and G. J. Thorbecke. Linkage of superantigen-like stimulation of syngeneic T cells in a mouse model of follicular center B cell lymphoma to transcription of endogenous mammary tumor virus. EMBO J. 12, 2313-2320, 1993.

T. Yoshimoto, E. Yoshimoto, and D. Meruelo. Identification of amino acid residues critical for infection with ecotropic murine leukemia retrovirus. J. Virol. 67, 1310-1314, 1993.

T. Yoshimoto, E. Yoshimoto, and D. Meruelo. Enhanced gene expression of murine ecotropic retroviral receptor and its human homologue in proliferating cells. J. Virol. 66, 4377-4381, 1992.

T. Yoshimoto, E. Yoshimoto, and D. Meruelo. Molecular cloning and characterization of a novel human gene homologous to the murine ecotropic retroviral receptor. Virology 185, 10-17, 1991.

T. Yoshimoto, Y. Saito, K. Sugibayashi, Y. Morimoto, T. Tsukada, K. Kanmatsuse, Y. Kodera, A. Matsushima, and Y. Inada. Targeting of urokinase by magnetic force. Drug Delivery System 4, 121-122, 1989.

Y. Inada, A. Matsushima, Y. Saito, T. Yoshimoto, H. Nishimura, and H. Wada. Synthetic polymer-protein hybrids: Modification of L-asparaginase with polyethylene glycol. In Multiphase biomedical materials. (Editors: T. Tsuruta and A. Nakajima) VNU Science Press, The Netherlands. pp. 153-166, 1989.

K. Takahashi, K. Ohwada, T. Yoshimoto, Y. Saito, Y. Kodera, A. Matsushima, and Y. Inada. Plasminogen endowed with magnetic property. J. Biotechnol. 8, 135-140, 1988.

T. Nishio, K. Takahashi, T. Yoshimoto, Y. Kodera, A. Matsushima, Y. Saito, and Y. Inada. Ester synthesis in benzene by polyethylene glycol-modified lipase from Pseudomonas fragi 22.39B. J. Biotechnol. 8, 39-44, 1988.

Y. Inada, K. Takahashi, T. Yoshimoto, Y. Kodera, A. Matsushima, Y. Tamaura, and Y. Saito. Application of PEG-enzyme and magnetite-PEG-enzyme conjugates for biotechnological processes.Trend. Biotechnol. 6, 131-134, 1988.

T. Yoshimoto, K. Ohwada, K. Takahashi, A. Matsushima, Y. Saito, and Y. Inada. Magnetic Urokinase: Targeting to fibrin clot. Biochem. Biophys. Res. Commun. 152, 739-743, 1988.

T. Mihama, T. Yoshimoto, K. Ohwada, K. Takahashi, S. Akimoto, Y. Saito, Y. Tamaura, and Y. Inada. Magnetic lipase absorbed to a magnetic fluid. J. Biotechnol. 7, 141-146, 1988.

T. Yoshimoto, A. Ritani, K. Ohwada, K. Takahashi, Y. Kodera, A. Matsushima, Y. Saito, and Y. Inada. Polyethylene glycol derivative-modified cholesterol oxidase soluble and active in benzene.Biochem. Biophys. Res. Commun 148, 876-882, 1987.

Y. Inada, K. Ohwada, T. Yoshimoto, S. Kojima, K. Takahashi, A. Matsushima, Y. Kodera, and Y. Saito. Fibrinolysis by urokinase endowed with magnetic property. Biochem. Biophys. Res. Commun. 148, 392-396, 1987.

T. Yoshimoto, T. Mihama, K. Takahashi, Y. Saito, Y. Tamaura, and Y. Inada. Chemical modification of enzymes with activated magnetic modifier. Biochem. Biophys. Res. Commun.145, 908-914, 1987.

T. Nishio, K. Takahashi, T. Yoshimoto, Y. Kodera, Y. Saito, and Y. Inada. Terpene alcohol ester synthesis by polyethylene glycol-modified lipase in benzene. Biotechnol. Lett. 9, 187-190, 1987.

T. Yoshimoto, Y. Saito, and Y. Inada. Non-clottable fibrinogen by photooxidation in blood plasma.Photochem. Photobiol. 45, 681-682, 1987.

T. Yoshimoto, S. G. Cao, Y. Saito, I. Imamura, H. Wada, and Y. Inada. Chemical modification of tryptophanase from E. coli with polyethylene glycol to reduce its immunoreactivity towards anti-tryptophanase antibodies. Enzyme 36, 261-265, 1986.

T. Yoshimoto, M. Nakata, S. Yamaguchi, T. Funada, Y. Saito, and Y. Inada. Synthesis of eicosapentaenoyl phosphatidylcholines by polyethylene glycol-modified lipase in benzene.Biotechnol. Lett. 8, 771-776, 1986.

T. Yoshimoto, H. Nishimura, Y. Saito, K. Sakurai, Y. Kamisaki, H. Wada, M. Sako, G. Tsujino, and Y. Inada. Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia. Jpn. J. Cancer Res. (Gann) 77, 1264-1270, 1986.

Y. Inada, K. Takahashi, T. Yoshimoto, A. Ajima, A. Matsushima, and Y. Saito. Application of polyethylene glycol-modified enzymes in biotechnological processes: Organic solvents-soluble enzymes. Trend. Biotechnol. 4, 190-194, 1986.

Y. Inada, T. Yoshimoto, A. Matsushima, and Y. Saito. Engieering physicochemical and biological properties of proteins by chemical modification. Trend. Biotechnol. 4, 68-73, 1986.

K. Takahashi, Y. Kodera, T. Yoshimoto, A. Ajima, A. Matsushima, and Y. Inada. Ester-exchange catalyzed by lipase modified with polyethylene glycol. Biochem. Biophys. Res. Commun. 131, 532-536, 1985.A. Matsushima, M. Okada, K. Takahashi, T. Yoshimoto, and Y. Inada. Indoxyl acetate hydrolysis with polyethylene glycol-modified lipase in benzene solution. Biochem. Int. 11, 551-555, 1985.

K. Takahashi, A. Ajima, T. Yoshimoto, M. Okada, A. Matsushima, Y. Tamaura, and Y. Inada. Chemical reactions by polyethylene glycol-modified enzymes in chlorinated hydrocarbons. J. Organ. Chem. 50, 3414-3415, 1985.

A. Ajima, T. Yoshimoto, K. Takahashi, Y. Tamaura, Y. Saito, and Y. Inada. Polymerization of 10-hydroxydecanoic acid in benzene with polyethylene glycol-modified lipase. Biotechnol. Lett. 7, 303-306, 1985.

T. Yoshimoto, K. Takahashi, A. Ajima, A. Matsushima, Y. Tamaura, Y. Saito, and Y. Inada. Activation and stabilization of asparaginase by anti-asparaginase IgG and its Fab. FEBS Lett. 183, 170-172, 1985.

K. Takahashi, T. Yoshimoto, Y. Tamaura, Y. Saito, and Y. Inada. Ester synthesis at extraordinarily low temperature of -3°C by modified lipase in benzene. Biochem. Int. 10, 627-631, 1985.

K. Takahashi, T. Yoshimoto, A. Ajima, Y. Tamaura, and Y. Inada. Modified lipase catalyzes ester synthesis in benzene, substrate specificity. Enzyme 32, 235-240, 1984.

K. Takahashi, H. Nishimura, T. Yoshimoto, M. Okada, A. Ajima, A. Matsushima, Y. Tamaura, Y. Saito, and Y. Inada. Polyethylene glycol-modified enzymes trap water on their surface and exert enzymic activity in organic solvents. Biotechnol. Lett. 6, 765-766, 1984.

K. Takahashi, A. Ajima, T. Yoshimoto, and Y. Inada. Polyethylene glycol-modified catalase exhibits unexpectedly high activity in benzene. Biochem. Biophys. Res. Commun. 125, 761-766, 1984.

Y. Inada, H. Nishimura, K. Takahashi, T. Yoshimoto, A. R. Saha, and Y. Saito. Ester synthesis catalyzed by polyethylene glycol-modified lipase in benzene. Biochem. Biophys. Res. Commun.122, 845-850, 1984.

K. Takahashi, H. Nishimura, T. Yoshimoto, Y. Saito, and Y. Inada. A chemical modification to make horseradish peroxidase soluble and active in benzene. Biochem. Biophys. Res. Commun.121, 261-265, 1984.

T. Yoshimoto, K. Takahashi, H. Nishimura, A. Ajima, Y. Tamaura, and Y. Inada. Modified lipase having high stability and various activities in benzene, and its re-use by recovering from benzene solution. Biotechnol. Lett. 6, 337-340, 1984.